How the product works:
Inhibits SGLT2 transporters in the kidneys
Enhances glucose excretion through urine
Reduces blood glucose levels and heart failure risk
Recommended for:
Adults diagnosed with type 2 diabetes
Patients with increased cardiovascular risk
Patients with uncontrolled HbA1c despite other treatments
Type 2 diabetes mellitus as monotherapy or combination therapy in adults
Taken orally once daily, with or without food, as prescribed by a healthcare professional.
Contraindications:
Hypersensitivity to Empagliflozin
Severe renal impairment
Pregnancy and lactation
Type 1 diabetes
Diabetic ketoacidosis
Side effects:
Frequent urination
Genital and urinary tract infections
Dehydration
Hypoglycaemia (with other antidiabetic agents)
Increased haematocrit